Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.
Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other di...
Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.
Autifony is using its pioneering approach to develop novel treatments for serious disorders of the central nervous system, such as Schizophrenia, Fragile X, Alzheimer’s Disease and potentially other diseases which represent major unmet medical needs.
The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.